Clinical Trial Update: To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

View source ↗

Summary

Astellas-sponsored trial evaluating fidaxomicin in neonates to assess Clostridioides difficile involvement has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Clostridium Difficile | Status: TERMINATED